EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

Wataru Sasaki iD, Ryo Saito iD, Kenta Suzuki, Daisuke Watanabe iD, Masako Minami-Hori, Hirofumi Kamada iD, Hiroo Amano iD, Akihiko Uchiyama iD, Sei-Ichiro Motegi iD, Machiko Kamura, Kazunari Sugita, Noriko Kubota und 13 weitere

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.17877 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Wataru Sasaki und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Drug Eruptions, Pruritus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study, we aimed to investigate the incidence, clinical characteristics, and timing of cutaneous manifestations associated with nemolizumab treatment in patients with AD, and to explore potential associations with baseline disease severity and immunological parameters. We conducted a multicenter retrospective study involving 219 patients aged ≥ 13 years with AD who received nemolizumab at 13 institutions in Japan between August 2022 and February 2024. Cutaneous eruptions were classified into six categories based on clinical consensus. Patients who received fewer than three doses without developing skin reactions were excluded. Clinical and laboratory parameters were compared between patients with and without cutaneous manifestations. Cutaneous manifestations occurred in 88 patients (40.2%), most commonly within the first three doses. Erythema was the most frequent presentation (69.3%), and 62.5% of eruptions were non‐pruritic. No significant associations were observed between the occurrence of skin reactions and baseline eczema area and severity index scores, eosinophil counts, serum immunoglobulin E, or thymus and activation‐regulated chemokine levels. Two cases of bullous pemphigoid were identified. Despite topical corticosteroid treatment, nemolizumab therapy was discontinued in 42% of the patients affected. In conclusion, nemolizumab frequently induces early‐onset, morphologically distinct cutaneous eruptions that appear to be independent of baseline disease severity or biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDrug EruptionsPruritusHumansRetrospective StudiesMaleFemaleJapanAdultMiddle AgedSeverity of Illness IndexRisk FactorsYoung AdultAdolescentIncidenceAged

Stichwörter der Autor:innen

atopic dermatitiscutaneous manifestationsimmunological markersnemolizumabpruritus

Substanzen

Antibodies, Monoclonal, Humanizednemolizumab

Autor:innen und Institutionen

  • Department of Dermatology, Hiroshima University, Hiroshima, Japan.
  • Department of Dermatology, Aichi Medical University, Nagakute, Aichi, Japan.
  • Department of Dermatology, Asahikawa City Hospital, Asahikawa, Hokkaido, Japan.
  • Department of Dermatology, Iwate Medical University, Iwate, Japan.
  • Department of Dermatology, Gunma University, Maebashi, Gunma, Japan.
  • Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

ORCID-Profile: Wataru Sasaki, Ryo Saito, Daisuke Watanabe, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei-Ichiro Motegi, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Ken Igawa, Yuka Kimura, Yoko Kataoka, Masakazu Takahashi, Akio Tanaka

Zitieren

APA

Sasaki, W., Saito, R., Suzuki, K., Watanabe, D., Minami-Hori, M., Kamada, H., Amano, H., Uchiyama, A., Motegi, S. I., Kamura, M., Sugita, K., Kubota, N., Nomura, T., Ozawa, M., Takahashi, T., Yamakita, T., Sugiura, K., Ikegami, T., Igawa, K., …, & Sugawara-Mikami, M. (2026). Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17877

Vancouver

Sasaki W, Saito R, Suzuki K, Watanabe D, Minami-Hori M, Kamada H, et al. Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.17877

BibTeX
@article{Sasaki2026,
  author = {Sasaki, Wataru and Saito, Ryo and Suzuki, Kenta and Watanabe, Daisuke and Minami-Hori, Masako and Kamada, Hirofumi and Amano, Hiroo and Uchiyama, Akihiko and Motegi, Sei-Ichiro and Kamura, Machiko and Sugita, Kazunari and Kubota, Noriko and Nomura, Toshifumi and Ozawa, Maki and Takahashi, Toshiya and Yamakita, Takashi and Sugiura, Kazumitsu and Ikegami, Tetsuharu and Igawa, Ken and Kimura, Yuka and Kataoka, Yoko and Kamide, Ryoichi and Takahashi, Masakazu and Tanaka, Akio and Sugawara-Mikami, Mariko},
  title = {Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.17877}
}
Kostenlos starten →